(Q80295422)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Kurata A

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Nishizawa H

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kihara S

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Maeda N

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sonoda M

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Okada T

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Ohashi K

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Hibuse T

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Fujita K

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Yasui A

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Hiuge A

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kumada M

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kuriyama H

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Shimomura I

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Funahashi T

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

20 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

1717-1724

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.ki.5001810

30 December 2019

exact match

0 references

cites work

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

The metabolic syndrome and chronic kidney disease in U.S. adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Association between microalbuminuria and the metabolic syndrome: NHANES III

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

The adipose tissue--a novel endocrine organ of interest to the nephrologist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Microalbuminuria, cardiovascular, and renal risk in primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Cardiovascular and renal risk assessment as a guide for treatment in primary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Obesity and the regulation of energy balance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Adiponectin and Metabolic Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Tumor necrosis factor alpha and mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Diet-induced insulin resistance in mice lacking adiponectin/ACRP30

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

The adipocyte-secreted protein Acrp30 enhances hepatic insulin action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Plasma adiponectin levels and risk of myocardial infarction in men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Adiponectin and development of type 2 diabetes in the Pima Indian population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Decreased plasma adiponectin concentration in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Adiponectin as a biomarker of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Increased oxidative stress in obesity and its impact on metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Mechanisms for the clinical benefits of angiotensin II receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Serum amyloid A3 expression is stimulated by dexamethasone and interleukin-6 in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Hyperglycemia-induced production of acute phase reactants in adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

PU.1 is essential for p47(phox) promoter activity in myeloid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

NAD(P)H oxidase: role in cardiovascular biology and disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Reactive oxygen species as mediators of angiotensin II signaling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001810

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001810

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985520%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

30 December 2019

0 references

1 reference